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therapy for nonmuscle-invasive bladder cancer: A need for more
randomized trials”Nonmuscle-invasive bladder cancer (NMIBC), that is, tumors
staged as Ta, T1, or carcinoma in situ (CIS), represents a heteroge-
neous group of tumors with varied oncological outcomes. Further
precise risk stratiﬁcation for predicting risk of recurrence and pro-
gression, and for determining the appropriate management strat-
egy is imperative.
Since it was ﬁrst introduced by Morales et al in 1976, intraves-
ical bacillus Calmette-Guerin (BCG) therapy has been established
as the standard treatment after transurethral resection (TUR) of
high-risk NMIBC. BCG therapy exhibits antitumor activity by trig-
gering a robust cellular immune response, although the precise
mechanism of action is not fully understood yet. Most practice
guidelines recommend maintaining BCG therapy for 1e3 years,1,2
whereas it is optional in others.3 Recently, the beneﬁt of mainte-
nance BCG therapy has been questioned. Based on a critical anal-
ysis of the current evidence, Herr et al4 claimed that maintenance
BCG therapy appeared to be not superior to the initial induction
BCG treatment in terms of preventing or retarding tumor progres-
sion; in addition, additional toxicity from prolonged BCG treat-
ment has been reported. The following factors contributing to
the current dilemmas in establishing the optimal duration of
maintenance BCG therapy have been addressed: lack of good qual-
ity patient data and long-term follow up for direct comparisons;
lack of evidence from indirect comparisons by meta-analyses;
and the impact of great variation in the quality of TUR. From the
literature review, ﬁrst, we should recognize that a variety of main-
tenance schemes are available, from one instillation given every 3
months to 21 instillations given over 3 years. Second, regarding
the efﬁcacy of maintenance of BCG on disease progression, only
one study demonstrated a reduction in disease progression,5 how-
ever, the progression was deﬁned as a “vague” composite end
point, including worsening-free survival including death due to
any cause; biopsy evidence of stage T2 or worse disease; or switch-
ing to another treatment strategy, such as cystectomy, systemic
chemotherapy, or radiotherapy, which implies disease progression
or worsening.5 Death due to any cause is a problematic end point.
Moreover, Lamm et al5 used a one-sided test for signiﬁcance, and
thus, established a low threshold to demonstrate a signiﬁcant
outcome. In addition, the efﬁcacy of maintenance instillation of
BCG for recurrence of NMIBC may also depend on the patient's tu-
mor characteristics, including stage, grade, and multifocality. How-
ever, Lamm et al5 did not report patients' tumor characteristics
prior to initiation of BCG therapy.http://dx.doi.org/10.1016/j.urols.2015.04.005
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier TaiwMaintenance BCG therapy is associated with cumulative
toxicity. Only 16% of patients in the Southwest Oncology Group trial
were able to complete the 3-year maintenance schedule,5 and only
36% of patients were able to toleratemonthly BCG instillations for 2
years.6 However, another study demonstrated that 80% of patients
completed a 3-year maintenance regimen and only 20% were
intolerant.7
Herr et al8 implemented a large cohort study of high-risk
bladder cancer patients (n ¼ 1021) who received BCG therapy
without maintenance. The results showed that 816 patients had a
complete response to BCG therapy, and their 2-year and 5-year
recurrence-free survival rates were 73% and 46%, respectively. In
addition, the progression-free survival rate was 89% and the
progression-free survival time was 56 months (95% conﬁdence in-
terval, 55e58 months).8 The authors claimed that the results
without maintenance BCG therapy have more favorable outcomes
compared with the trials with maintenance BCG therapy. They
also advocated that relapsing patients can be salvagedwith retreat-
ment BCG rather than be exposed to the toxicity resulting from
maintenance BCG therapy.
In addition to the aforementioned knowledge, we also look into
the study by Liu et al9d“Maintenance reported bacillus Calmette-
Guerin therapy prolongs recurrence-free survival in non-muscle
invasive bladder cancer”dpublished in this issue of Urological Sci-
ence. However, this retrospective study was unable to afford ran-
domized trials, and therefore, its results should be interpreted
cautiously. Moreover, the study population remained heteroge-
neous, and was not classiﬁed according to the low-risk tumors [pri-
mary, solitary, Ta, low grade/G1, <3 cm, and no CIS], intermediate-
risk tumors [between the category of low and high risk], and
high-risk tumors [any tumor in stage T1, high grade/G3 tumor,
CIS, and multiple and recurrent and large (>3 cm) Ta, G1, and G2 tu-
mors] proposed by the European Association of Urology guideline.1
Because BCG therapy was known to not alter the natural course of
low-risk tumors, it could be considered as overtreatment for this
category. For intermediate-risk tumors, 1-year maintenance of
full-dose BCG seems to be more effective to prevent recurrence,
however, it is suggested to have more side effects when compared
with chemotherapy. Therefore, both maintenance BCG therapy and
intravesical chemotherapy remain as possible options.1 In this
cohort, 14.5% of patients were contaminated with previous intra-
vesical chemotherapy agents. The study results also did not
mention how many patients tolerated well beyond maintenancean LLC. Open access under CC BY-NC-ND license.
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vival data were provided. Nevertheless, this study indeed reﬂected
the potential of the real-world clinical practice pattern of BCG ther-
apy for NMIBC in Taiwan.
In conclusion, based on available evidence, BCG remains as the
effective intravesical agent for preventing NMIBC recurrence, how-
ever, its role in disease progression remains controversial.10 The
optimal number of induction instillations and the optimal fre-
quency and duration of maintenance instillations remains to be
determined. Further multicenter prospective randomized trials
are needed to investigate whether maintenance of BCG is most
beneﬁcial.
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